Table 1.

Inclusion and exclusion criteria of the SCIENCE trial

Inclusion criteria

Exclusion criteria

30–80 years of age Signed informed consent Chronic stable ischaemic heart disease Symptomatic HF (NYHA class II–III) LVEF ≤ 45% on echocardiography, CT or MRI scan Plasma NT‐proBNP > 300 pg/mL (> 35 pmol/L) Maximal tolerable HF medication unchanged 2 months prior to inclusion No option for PCI or CABG Patients who have had PCI or CABG within 6 months of inclusion must have a new coronary angiography to rule out early restenosis Patients cannot be included until 3 months after implantation of a CRT‐D and until 1 month after an ICD unit

HF NYHA class I or IV Acute coronary syndrome within 6 weeks of inclusion Other revascularization treatment within 4 months of treatment Moderate to severe aortic stenosis (valve area < 1.3 cm2) or valvular disease with option for surgery or interventional therapy Aortic valve replacement with an artificial heart valve. However, a trans‐septal treatment approach can be considered in these patients If the patient is expected to be candidate for MitraClip therapy Diminished functional capacity for other reasons such as COPD with FEV1 < 1 L/min, moderate to severe claudication or morbid obesity Clinical significant anaemia (Hb < 6 mmol/L), leukopenia (leucocytes < 2 × 109/L), leukocytosis (leucocytes > 14 × 109/L) or thrombocytopenia (thrombocytes < 50 × 109/L) Reduced kidney function (eGFR < 30 mL/min) Left ventricular thrombus Anticoagulation treatment that cannot be paused during cell injections Patients with reduced immune response or known anti‐HLA antibodies History with malignant disease within 5 years of inclusion or suspected malignancy – except treated skin cancer other than melanoma Pregnant women Other experimental treatment within 4 weeks of baseline tests Life expectancy < 1 year Participation in another intervention trial Known hypersensitivity to DMSO, penicillin and streptomycin

CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; CRT‐D, cardiac resynchronization therapy with defibrillation; CT, computed tomography; DMSO, dimethyl sulfoxide; eGFR, estimated glomerular filtration rate; FEV₁, forced expiratory volume in 1 s; Hb, haemoglobin; HF, heart failure; HLA, human leucocyte antigen; ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; MRI, magnetic resonance imaging; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; NYHA, New York Heart Association; PCI, percutaneous coronary intervention.